Ongoing phase III immunotherapy trials in mCRPC
| Trial | National clinical trial identifier | Status* |
|---|---|---|
| PSA-TRICOM +/- GM-CSF | NCT01322490 | Ongoing, Expected completion date June 2017 |
| Tasquinimod | NCT01234311 | Completed, Reported in 2016 [61] |
| Ipilimumab in chemo-naïve mCRPC | NCT01057810 | Completed, Reported in 2016 [38] |
* As determined by ClinicalTrials.gov accessed October 31, 2016